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The scaffold protein syntenin abounds during fetal life where it is important
for developmental movements. In human adulthood, syntenin gain-of-function is
increasingly associated with various cancers and poor prognosis. Depending on the
cancer model analyzed, syntenin affects various signaling pathways. We previously
have shown that syntenin allows syndecan heparan sulfate proteoglycans to escape
degradation. This indicates that syntenin has the potential to support sustained
signaling of a plethora of growth factors and adhesion molecules. Here, we aim to
clarify the impact of syntenin loss-of-function on cancer cell migration, growth, and
proliferation, using cells from various cancer types and syntenin shRNA and siRNA
silencing approaches. We observed decreased migration, growth, and proliferation of
the mouse melanoma cell line B16F10, the human colon cancer cell line HT29 and the
human breast cancer cell line MCF7. We further documented that syntenin controls the
presence of active β1 integrin at the cell membrane and G1/S cell cycle transition as well
as the expression levels of CDK4, Cyclin D2, and Retinoblastoma proteins. These data
confirm that syntenin supports the migration and growth of tumor cells, independently
of their origin, and further highlight the attractiveness of syntenin as potential therapeutic
target.
Keywords: syntenin, PDZ proteins, syndecan, cancer cell migration, cancer cell growth, cancer cell proliferation,
cell cycle
INTRODUCTION
Syntenin is strongly expressed during human fetal life and at relatively low levels in adult tissues
(Zimmermann et al., 2001). Loss-of-function studies in Xenopus and zebraﬁsh indicated that
syntenin plays an important role in early developmental movements by controlling the non-
canonical Wnt-signaling pathway (Luyten et al., 2008; Lambaerts et al., 2012), among others. Loss
of syntenin function in mice has comparatively little eﬀects. Indeed, Tamura et al. (2015) recently
reported a mild phenotype in intestinal homeostasis.
Syntenin is detectable in adult human tissues, but an increasing number of independent
studies indicate that syntenin is overexpressed in various patient tumor samples. Syntenin gain-
of-function was ﬁrst described in metastatic melanoma (Helmke et al., 2004), and more recently
in breast cancer (Qian et al., 2013; Yang et al., 2013) and in multiple neuroepithelial tumors
(Kegelman et al., 2014) suggesting that syntenin could be a tumor marker. For example, in breast
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cancer patients, the correlation between syntenin expression,
tumor size, lymph node status, and recurrence appears
statistically signiﬁcant (Yang et al., 2013).
In cellular models, by in vitro but also in vivo approaches
with xenografts, several studies have shown that elevated syntenin
expression is particularly relevant for invasion and metastasis
(Koo et al., 2002; Boukerche et al., 2005; Das et al., 2013;
Liu et al., 2014). Depending on the cellular context, syntenin
has been associated with the activation of various signaling
pathways, including SRC/p38MAPK/NFkB in human melanoma
(Boukerche et al., 2005, 2007, 2008, 2010), in human glioblastoma
multiform (GBM) (Kegelman et al., 2014), and in head and neck
squamous cell carcinoma angiogenesis (Oyesanya et al., 2014),
integrin β1/ERK1/2 in human breast cancer cells (Yang et al.,
2013), EGFR/Akt/PI3K in urothelial cell carcinoma (Dasgupta
et al., 2013), HIF-1α/IGFBP-2 in human melanoma angiogenesis
(Das et al., 2013), and STAT3/PI3K/CTNNB1 in head and neck
squamous cell carcinoma angiogenesis (Oyesanya et al., 2014).
Syntenin is a scaﬀold protein containing two Post synaptic
density-95, Disc-large tumor suppressor and Zonula occludens-
1 (PDZ) domains that we originally identiﬁed as an intracellular
adaptor for the syndecan family of heparan sulfate (HS)
proteoglycans (Grootjans et al., 1997). HS proteoglycans are
highly abundant in adherent cells and their HS chains have
numerous ligands, including various morphogens, adhesion
molecules, and growth factors, such as Wnts, ﬁbronectin
and FGFs, whose deregulated signaling is involved in cancer
development and progression (Fuster and Esko, 2005).HS plays
an important role in the docking of these factors to cognate
signaling receptors and can connect and regulate many signaling
systems in a cell-type and cell-context dependent manner.
Besides interacting with syndecans, the PDZ domains of syntenin
can also directly interact with various membrane proteins and
receptors (Beekman and Coﬀer, 2008), including Frizzled Wnt
receptors that can rely on syndecans for their functions (Luyten
et al., 2008). In structure–function studies, we demonstrated
that syntenin allows syndecans and associated molecules to
escape degradation by promoting their recycling to the plasma
membrane (Zimmermann et al., 2005) or their secretion as
exosomal cargo (Baietti et al., 2012; Ghossoub et al., 2014; Friand
et al., 2015; Roucourt et al., 2015). These studies are entirely
consistent with the observation that syntenin can boost various
signaling pathways when overexpressed in cancer cells. The
functional versatility of syndecans also explains that syntenin
gain-of-function can support various signaling pathways and that
speciﬁc eﬀects can be cell-type dependent.
As a starting point to evaluate the potential beneﬁt of anti-
syntenin drugs, we here aimed to document and compare the
impact of syntenin loss-of-function on the migration, invasion,
growth, and proliferation of various model cancer cell lines.
MATERIALS AND METHODS
Cell Culture and Transient Transfections
HT29, MCF7, and B16F10 cell lines were purchased from
the American Type Culture Collection (Manassas, VA, USA).
HT29 cells were grown in McCoy’s medium (Thermoﬁsher
Scientiﬁc), MCF7 cells in DMEM-F12 medium (Thermoﬁsher
Scientiﬁc), and B16F10 cells in DMEM medium (Thermoﬁsher
Scientiﬁc). Media were supplemented with 10% fetal bovine
serum (FBS) (Thermoﬁsher Scientiﬁc) and cells were incubated
at 37◦C under 5% CO2. For transient expressions, cells were
plated 24 h earlier at a density of 1 × 105 cells per well
in six well plates (BD Falcon) with 2 ml medium. 4 μl of
Fugene HD reagent (Roche Applied Sciences) were added to
200 μl Opti-MEM solution (Thermoﬁsher Scientiﬁc) and 1 μg
plasmid DNA. The mixture was incubated for 20 min at
room temperature before being added to the cells. For RNAi
experiments, cells at a conﬂuence of 50% were transfected
with 20 nM RNAi using Lipofectamine RNAiMAX reagent
(Life technologies, USA). Cells were analyzed after indicated
time.
Expression Vectors and Reagents
RNAis targeting Syntenin and the non-targeting control RNAi
(si Ctrl) were purchased from GE healthcare Dharmacon Inc
(Human syntenin (5′-GCAAGACCUUCCAGUAUAA-3′),
Mouse syntenin smartpool (M-043821-01)). For rescue
experiments, syntenin cDNA was cloned in pcDNA3.1/Zeo(+)
(Thermoﬁsher Scientiﬁc) and mutated by directed mutagenesis
on three nucleotides in the sequence targeted by the siRNA
(CCTTCCAGTmutated to CCGTCGAGC).
Empty vector, control shRNA and the 29 mer human and
mouse shRNA sequences cloned in pGFP-V-RS vector were
purchased from Origene [control shRNA GCACTACCAGAGC
TAACTCAGATAGTACT (TR30013), Human syntenin shRNA 2
(GCCTAATGGACCACACCATTCCTGAGGTT(TG309594B/G
I338370), shRNA 3 (GTGGCTCCTGTAACTGGTAATGATGTT
GG (TG309594C/GI338371), Mouse shRNA (TCAGGCTCAAA
CTGCTTATTCTGCCAATC (TG512166A/GI574570)].
Statistical Analysis
Statistical Analysis was performed using the standard two-
tailed Student t-test, and ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001
were considered statistically signiﬁcant. Metamorph, Image J
and ColonyDoc-It acquired data were processed with GraphPad
Prism software.
Preparation of Cancer Cell Lines
Depleted in Syntenin
Empty vector, control shRNA, and syntenin shRNAs expression
vectors for mouse and human syntenin were transfected in
phoenix packaging cells [ecotropic for Mouse and amphotropic
for human cells (Life Technologies)]. Viral supernatants were
harvested after 24–48 h intervals and used to infect cells for
48 h. Stable populations were selected for 10 days using optimal
concentrations of puromycin as tested ﬁrstly on non-transduced
cells (minimal concentration for death).
Generation of Syntenin Antibody
For the immunization, two rabbits were injected with two
peptides, respectively, NEAEICESMPMVSGA and PSIM-
KSLMDHTIPEV, corresponding to sequences found in the
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N-Terminal and the C-terminal part of mouse syntenin-1
(Eurogentec). Crude sera from the two rabbits were pooled.
Anti-syntenin antibodies were puriﬁed using the C-terminal
peptide antigen with a carboxy terminal cysteine and a
thiopropyl sepharose 6B column (Amersham). The unbound
proteins were washed with sodium phosphate buﬀer. Antibodies
were eluted with 0.1 mM glycine pH 2.5. Puriﬁed antibodies
were immediately brought back to pH 7.5 using a solution of
1.5 mM TRIS-HCl pH 8.5. Antibodies were dialyzed overnight
against PBS containing 0.01% sodium azide, 0.1% BSA, pH
7.5 overnight at 4◦C and aliquots were stored at −20◦C. The
puriﬁed antibodies were shown to recognize mouse and human
syntenin-1 using recombinant proteins. Their reactivity was
lost on syntenin-1 CRISPR-Cas9 knock-out human cells and
ﬁbroblasts originating from syntenin-1 knock-out mice, attesting
for their speciﬁcity.
Western Blotting
Cells were plated in 10 cm diameter dishes. After 48 h, cell
lysates were fractionated by SDS-PAGE and transferred to
nitrocellulose membranes (GE Healthcare Life sciences). The
membranes were blocked with 5% fat free milk and incubated
with primary antibodies against Syntenin (homemade, see
generation of syntenin antibody paragraph), β Actin (Santa Cruz,
sc-69879), Tubulin (Sigma–Aldrich, USA), Cyclin D2 (Santa
Cruz, sc-593), CDK4 (Cell signaling #2906), Retinoblastoma
(BD Biosciences # 554136), and HRP-conjugated secondary
antibodies. The membranes were washed with PBS/0.1% Tween
buﬀer and antibody binding was revealed using enhanced
chemiluminesescence (ECL) reagent (Thermo Scientiﬁc)
according to the recommendations of the manufacturer. Signals
were detected on photographic ﬁlms (GE healthcare).
Wound Healing Assay
Cells were treated with 1 ng/ml mitomycin (Sigma M4287)
overnight to inhibit cell division. Treated cells were plated in
Ibidi culture-inserts (Ibidi Cat-80206) for 12 h to reach 90–95%
of conﬂuence. A wound was created by removing inserts from
the dishes. Medium was refreshed to remove dead cells and the
cells were observed under an inverted light microscope (Leica
SP2) equipped with a camera. Images were taken by MetaMorph
software every 10 min for 24 h. Measurements of cell velocity
were calculated using the MetaMorph software.
Transwell Migration Assay
Cells were serum starved and treated with 1 ng/ml of mitomycin
(Sigma M4287) for 12 h to inhibit cell division. Upper chambers
(8 μm pores, Becton Dickinson, USA) cell chambers were placed
in 24-well format transwell plates. Starved cells were plated in
assay media (200 μl) (20 000 cells/well in the upper chamber).
Lower chambers were pre-coated for 2 h with rat tail collagen
I (Roche). To initiate migration, media containing 10% serum
(600 μl) was placed in the lower chamber as attractant. After
48 h of incubation, cells were washed with PBS, ﬁxed with 4%
paraformaldehyde for 10 min, and stained with 0.5% crystal
violet for 15 min at room temperature. Inserts were washed
with PBS and air dried for 15 min. Cells on the upper side
(non-migrating) of the ﬁlter were removed by swabbing with
cotton wool. Migrating cells were imaged on a Zeiss Axioskop
2 ﬂuorescence microscope using a 10x objective (Zeiss, NA 0.3)
and a Spot RT/SE CCD camera (Diagnostics) in mosaic format.
Cells were counted using ImageJ software cell counter.
Plate Colony Formation Assay
Cells were counted using Malassez slides and seeded at 1000 cells
per 6 cm diameter dish in the usual media for each cell line
(see above). The culture media was changed every 5 days. After
incubation for 14 days, cells were washed with PBS, ﬁxed with 4%
paraformaldehyde for 10min, and stained with 0.5% crystal violet
for 15 min at room temperature. Pictures were taken; visible
colonies were counted using an automatic colony counter (UVP,
ColonyDoc-ItTM Imaging Station).
Soft Agar Colony Formation Assay
Agarose was melted in water and mixed with medium pre-
incubated at 37◦C at end-concentrations of 0.6 or 0.36%. A lower
layer (0.6% agarose) was deposited in each well of a 96 well
plates, except for the ﬁrst and last rows and columns that were
ﬁlled with PBS to avoid drying. Agarose was allowed to cool for
15 min before addition of the upper layer containing 2000 cells
and 0.36% agarose. Plates were incubated at 37◦C for 21 days in
a 5% CO2 incubator and observed under a microscope at 24 h
intervals. At the end of the experiments, cells were tested for
their ATP content, an indicator of their metabolic activity, using
the Promega kit G7570. In this assay, ATP is used as a co-factor
for a luciferase reaction. Signals were analyzed by measuring
luminescence with a LUMI starluminometer (BMG Labtech).
Cell Proliferation
1 × 105 cells were plated in 6 cm diameter dishes in six well
culture plates. At each time point, a plate from each cell line was
trypsinised, cells were collected in 2 ml of media and stained with
Trypan blue. Cell counting was performed with Countess R© Cell
Counting Chamber Slides (Thermo ﬁsher C10228).
Immunofluorescence Staining and
Confocal Microscopy
Cells were cultured on glass coverslips, ﬁxed with 4% PFA
for 15 min, washed in PBS and then incubated with Integrin
β1 antibody (BD 553715) in PBS containing 0.3% BSA and
0.05% saponin. Coverslips were mounted in DABCO/Mowiol
and observed with a Zeiss Meta confocal microscope (LSM 510
META, Zeiss, France) with a UV laser and a 40× objective.
Confocal images were analyzed and mounted using Photoshop
(Adobe, San Jose, CA, USA) software.
Cell Cycle Analysis
MCF7 cells were transfected with non-targeting and Syntenin
siRNAs in 10% serum. After 24 h cells were synchronized in G1
phase by serum starvation for 24 h. After synchronization, cell
cycle entry was recovered in fresh media and cells were analyzed
at diﬀerent time points. Therefore, cells were washed with cold
PBS and ﬁxed in 70% ethanol at 4◦C for 30 min. After ﬁxation
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cells were stained with a 20 μg/mL propidium iodide solution
(PBS containing 40 μg/mL RNase A) for 30 min at 37◦C. Cell
cycle distribution in G1, S, and G2/M phases was analyzed on
the BD LSRFORTESSA (BD Biosciences) ﬂow cytometer. The
percentage of cells in each cell cycle phase was analyzed by FACS
Diva software.
RESULTS
Generation and Validation of Various
Cancer Cell Lines Depleted in Syntenin
To evaluate the impact of syntenin loss-of-function in cancer
cells, we selected three diﬀerent models: mouse melanoma
B16F10 (mixture of spindle-shaped and epithelial-like cells,
mutated for p53, RAS wild-type, highly metastatic and invasive),
Human colorectal adenocarcinoma HT29 (epithelial cells,
mutated for p53, RAS wild-type, highly metastatic, and invasive)
and Human breast adenocarcinoma MCF7 (epithelial cells,
ER-positive, p53, and RAS wild-type, non-metastatic, poorly
invasive). B16F10 and HT29 cells, express higher levels of
syntenin in comparison to MCF7 cells (Figure 1A). To generate
cell populations stably depleted for syntenin, we used retroviral-
mediated gene transduction of small hairpin RNAs (shRNA). One
shRNA molecule (shRNA) and two diﬀerent shRNA molecules
(shRNA2 and 3) were used to eﬃciently knockdown syntenin
expression in mouse and human cells, respectively (Figure 1B).
After selection, the levels of syntenin were assessed by Western
blot. The control shRNA, used as control, did not signiﬁcantly
aﬀect syntenin expression when compared to empty vector
transduced cells. shRNA targeting syntenin induced a signiﬁcant
decrease in syntenin expression in B16F10 cells (down by 80%
compared to control levels), in HT29 cells (down by 70 and
75% compared to control levels for the two diﬀerent shRNA,
respectively) and in MCF7 cells (down by 60 and 65% compared
to control levels for the two diﬀerent shRNA, respectively)
(Figure 1C).
Syntenin Loss-of-function Impairs Cell
Migration
We then evaluated the eﬀect of syntenin silencing on the
migratory potential of the various cell lines. We measured
cellular migration in wound healing (Figure 2A and
Supplementary Figure 1A) and transwell migration assays
(Figure 2B and Supplementary Figure 1B). To exclude any
inﬂuence of cell proliferation on cell migration, we performed
our experiments in the presence of 1 ng/ml of mitomycin to
block cell division (Dow et al., 2007). Control shRNA, used
as control, did not aﬀect syntenin migration signiﬁcantly
when compared to empty vector transduced cells. shRNA
targeting syntenin induced a signiﬁcant decrease in cellular
migration by wound healing assay in B16F10 cells (down by
44% compared to control levels), in HT29 cells (down by
35 and 37% compared to control levels for the two diﬀerent
shRNA, respectively) and in MCF7 cells (down by 28 and
35% compared to control levels for the two diﬀerent shRNA,
respectively) (Figure 2A). shRNA targeting syntenin also
induced a signiﬁcant decrease in cellular migration in transwell
migration assays in B16F10 cells (down by 38% compared to
control levels), in HT29 cells (down by 28 and 30% compared
to control levels for the two diﬀerent shRNA, respectively) and
in MCF7 cells (down by 35 and 36% compared to control levels
for the two diﬀerent shRNA, respectively) (Figure 2B). In an
attempt to identify mechanisms that could explain perturbed
migration, we compared the tubulin cytoskeleton pattern, as
well as the membrane distribution of active integrin β1 in
control and syntenin-depleted cells in regular 2D cultures.
While tubulin cytoskeleton did not display drastic diﬀerences
(data not shown), the plasma membrane/cell borders staining
of the active form of integrin β1 was clearly less marked in
syntenin-depleted cells than in controls (shown for B16F10 cells)
(Figure 2C). Altogether, these results indicate that syntenin
expression supports B16F10, HT29 and MCF7 cancer cell
migration.
Syntenin Loss-of-function Impairs
Anchorage-independent Cell Growth and
Cellular Proliferation
The role of syntenin in cell growth was investigated using
in vitro plate colony formation assays (Figures 3A,B) and soft
agar colony formation assays (Figures 3C,D). The number
of colonies was signiﬁcantly decreased in syntenin-depleted
B16F10, HT29, and MCF7 cells compared to control cells, i.e.,
cells expressing empty vectors. In MCF7 cells, two diﬀerent
shRNA induced a drastic reduction of plate colony formation,
decreasing, respectively, by 85 and 88% compared to control.
In B16F10 and HT29 cells, the reduction of colony numbers
was less drastic but still signiﬁcant, with a decrease by 30%
in B16F10 and by 36 or 38% in HT29 cells depending on the
shRNA (Figures 3A,B). We also performed soft agar colony
formation assays to test cellular abilities to form colonies in
three dimensions because this assay is considered as the most
stringent test for the detection of anchorage-independent tumor
cell growth (Horibata et al., 2015). shRNA targeting syntenin
induced a 49% decrease in the growth of B16F10 cells, a 20 or 33%
decrease in the growth of HT29 cells and a 44 or 46% decrease in
the growth of MCF7 cells (respective values for the two diﬀerent
shRNA) (Figures 3C,D). Control shRNA, used as control, did not
signiﬁcantly aﬀect colony formation, neither in plate nor in soft
agar assays, when compared to empty vector transduced B16F10
andHT29 cells. Surprisingly, control shRNA signiﬁcantly aﬀected
colony formation of MCF7 cells in both assays. The reason for
this speciﬁc eﬀect in MCF7 cells is unknown. While a priori
this observation does not change the conclusion that syntenin
depletion aﬀects the growth of MCF7 cells, it indicates that from
a quantitative point of view, data should be interpreted with
caution.
We also tested the eﬀect of syntenin depletion by transiently
downregulating syntenin expression, using small interfering
RNA (siRNA). Eﬀective syntenin knockdown by mouse and
human syntenin siRNAs over a period of 4 days was validated
by Western blot analysis (Figure 4A). In these experiments,
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FIGURE 1 | Generation of cells with stable syntenin knockdown. (A) Western blots illustrating Syntenin basal expression in B16F10, HT29, and MCF7 cells,
data are from the same blot. Actin was used as a loading control. (B) Western blots illustrating Syntenin expression levels after viral transduction with various
constructs, as indicated. One small hairpin RNA (mSynt shRNA) and two different shRNA molecules (hSynt shRNA2 and hSynt shRNA3) were used to efficiently
knockdown syntenin expression in mouse (B16F10) and human cells (HT29 and MCF7), respectively. Empty vector and ctrl shRNA were used as controls. Tubulin
was used as a loading control. (C) Bar graphs indicate the average levels of syntenin expression, expressed relative to levels in empty vector transduced cells (taken
as 100%). n = 3, bars represent mean value ± SD, n.s., non-significant, ∗P < 0.05, ∗∗P < 0.01 (Student’s t-test).
syntenin expression was downregulated by 90–95% compared
to controls. We tested the proliferation of B16F10, HT29, and
MCF7 cells transiently transfected with non-targeting control
siRNA (si Ctrl) and syntenin siRNA (si Syntenin) by counting
the number of viable cells every day over a period of 5 days
(Figure 4B). Control B16F10 and HT29 cells (si Ctrl) showed
a 30-fold increase in cell number after 5 days, while control
MCF7 cells showed a 20-fold increase. Syntenin-depleted B16F10
and HT29 cells (siSyntenin) showed a 15-fold increase in cell
number after 5 days, while syntenin-depleted MCF7 cells showed
a 10-fold increase. A signiﬁcant diﬀerence between controls and
syntenin-depleted cells was observed in all models at day 2 and
later times (Figure 4B). An eﬀect of syntenin depletion on cell
death could be ruled out because we observed in controls and
syntenin depleted cells a similar extremely low number of Trypan
blue (Supplementary Figure 2) and annexin-V positive cells
(Supplementary Figure 3). To further validate syntenin eﬀects
on cellular proliferation, we also performed rescue experiments
with MCF7 cells. Cells were treated with control (si Ctrl) and
syntenin siRNAs (si Syntenin) for 24 h and then transiently
transfected with an expression vector for wild-type syntenin
mutated for the siRNA targeting sequence (syntenin OE) or
the empty vector as a control. Total cell lysates analyzed by
Western blot indicated rescue of syntenin expression above the
control levels in MCF7 cells at 48h (Figure 4C), but these levels
were still in the physiological range commonly observed in cell
cultures. Rescued MCF7 cells showed a signiﬁcant improvement
of proliferation at day 2 and later, and 30-fold increase in cell
number after 5 days of culture (Figure 4D). We assume that this
increase in proliferation (by a factor 1.5 at day 5 when compared
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FIGURE 2 | Syntenin loss-of-function reduces the migration of mouse and human cancer cells. (A) Left: Phase-contrast micrographs illustrating migration
by wound healing of B16F10 cells monolayers transduced with empty vector, control, or syntenin shRNA. Images were taken at different time points after wounding,
as indicated. Right: Bar graphs indicate gap closures relative to closure in empty vector transduced cells (taken as 100%). n = 3, bars represent mean value ± SD,
n.s., non-significant, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (Student’s t-test). (B) Left: Micrographs illustrating transwell-migration of B16F10 cells transduced with
empty vector, control or syntenin shRNA. Right: Bar graphs indicate trans-migration relative to empty vector transduced cells (taken as 100%). Note that
syntenin-depleted cells always migrate more slowly than control cells. n = 3, bars represent mean value ± SD, n.s., non-significant, ∗∗P < 0.01, ∗∗∗P < 0.001
(Student’s t-test). (C) Confocal micrographs illustrating active integrin β1 staining (red in merge, blue corresponds to DAPI staining of the nuclei) in B16F10 cells
treated with control (Ctrl) or syntenin siRNA (syntenin -), as indicated. Note the integrin β1 staining at the cell borders in controls (arrows) but not in syntenin-depleted
cells. Scale bar, 10 μm.
to control cells-Si Ctrl in Figure 4B), might result from the
slight gain of syntenin expression in rescued cells. Altogether, the
above data indicate that syntenin supports the capacity of single
cells to form colonies, anchorage-independent cell growth, and
proliferation in B16F10, HT29, and MCF7 cells and that cellular
proliferation might be directly correlated to syntenin expression
levels.
Syntenin Loss of Function Impairs G1/S
Cell Cycle Transition
To better understand the eﬀect of syntenin loss-of-function
on cell growth and proliferation, we tested whether cells were
arrested in a particular phase of the cell cycle. Syntenin-depleted
(si Syntenin) and control (si Ctrl) MCF7 cells were synchronized
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FIGURE 3 | Syntenin loss-of-function leads to reduced growth in different cancer cell models. (A) Representative images of colony formation assays with
the different cell models. (B) Bar graphs indicate the number of colonies formed relative to colony numbers formed by empty vector-transduced cells (taken as
100%). n = 3, bars represent mean value ± SD, n.s., non-significant, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (Student’s t-test). (C) Representative images of soft agar
colony formation assays with the different cell models. (D) Bar graphs indicate luciferase activities expressed in relative light units (RLUs), relative to activities
measured in empty vector transduced cells (taken as 100%). Note that syntenin-depleted cells grow more slowly than the control cells. n = 3, bars represent mean
value ± SD, n.s., non-significant, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (Student’s t-test).
by serum starvation for 24 h. Cells were then serum-stimulated
for 24 h and analyzed for diﬀerent cell cycle phases by ﬂow
cytometry. Syntenin-depleted cells showed a signiﬁcant increase
in G1 phase and a signiﬁcant decrease in S andG2/Mphases when
compared to control cells (Figure 5A). The eﬀects of serum-
stimulation on the diﬀerent phases of the cell cycle were also
analyzed at diﬀerent time points over a period of 2 days in
two independent experiments; see Figure 5B for one illustration.
At early time points (from 0 to 12 h), control and syntenin-
depleted cells did not show drastic diﬀerences in G1 phase (on
average 73% in controls and 71% in depleted cells) but the
percentage of S phase in control cells was twice more important
compared to syntenin-depleted cells (on average 5.5% in controls
and 2.5% in depleted cells). Starting from 18 h, S phase was
increased to reach 19% at 48 h in control cells, while in syntenin-
depleted cells, S phase poorly increased over time to reach at
maximum 6% after 48h of serum stimulation. Moreover, the
ratio of cells in G1, S, and G2/M stayed quite constant all along
the experiment in syntenin depletion conditions on the contrary
to what we observed in controls (Figure 5B). Taken together,
these data suggest that syntenin depletion induces a defect in
G1/S cell cycle transition. Of prime importance in this process
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FIGURE 4 | Syntenin loss-of-function leads to reduced proliferation in different cancer cell models. (A) Western blots illustrating syntenin expression levels,
at different time point, in B16F10, HT29, and MCF7 cells, after transfection with non-targeting (Si Ctrl) or syntenin (Si Syntenin) siRNAs. Tubulin was used as a
loading control. (B) Bar graphs indicate the absolute number of living cells measured after different days of culture, as indicated. Note that significant differences
were already observed at day 2. n = 3, bars represent mean value ± SD, n.s., non-significant, ∗P < 0.05 (Student’s t-test). (C) Western blots illustrating Syntenin
expression levels in MCF7 cells 48 h after transfection with different constructs, as indicated. SiRNA Syntenin (Si Syntenin); non-targeting siRNA (Si Ctrl); expression
vector for human Syntenin non-tagged and mutated for the siRNA targeting sequence (Syntenin OE); empty expression vector (Empty vector). Tubulin was used as
loading control. (D) Bar graph indicating the absolute number of living MCF7 cells in Syntenin rescue experiments after different days in culture. n = 3, bars represent
mean value ± SD, n.s., non-significant, ∗P < 0.05, ∗∗P < 0.01 (Student’s t-test).
is cyclin D2, which binds and activates cyclin-dependent kinases
4 (CDK4), thereby phosphorylating Retinoblastoma protein (Rb)
and promoting progression from mid to late G1 (Sherr, 1994).
We therefore tested for the expression levels of these three cell
cycle regulators of G1/S transition by Western blot and observed
that they are all signiﬁcantly downregulated in syntenin-depleted
cells compared to control cells (Figures 5C,D). Altogether, our
data indicate that syntenin might control cell growth by acting
on G1/S cell cycle transition.
DISCUSSION
Distinct assays and diﬀerent cancer cell types (melanoma, colon
and breast) from various origins (mouse and human) were used
in this study to investigate the eﬀects of syntenin knockdown.
All assays showed that syntenin depletion signiﬁcantly decreases
tumor cell migration, growth, and proliferation. Our results with
the commonly used B16F10 cells corroborate previously reported
studies with other mouse melanoma models showing that
syntenin overexpression promotes melanoma invasion, motility
and anchorage-independent growth (Boukerche et al., 2005).
Additionally, our experiments in human colon HT29 cells, show
that depletion of syntenin reduces cellular migration, growth
and proliferation. This is consistent with a study from Lee et al.
(2011) showing that syntenin gain of function stimulates the
migration of HT29 cells, and other colon cancer cells in transwell
assays, while syntenin knockdown by siRNAs have the opposite
eﬀects (Lee et al., 2011). Although not directly tested in HT29,
the same study also illustrated a role for syndecan-2-syntenin
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FIGURE 5 | Downregulation of syntenin impairs cell cycle G1/S transition in MCF7 cells. (A) Bar graph representing the percentage of cells in G1, S, and
G2/M cell cycle phases after synchronization. Cells were transfected with non-targeting siRNA (Si Ctrl) or Syntenin siRNA (Si Syntenin). n = 5, bars represent mean
value ± SD, ∗P < 0.05 (Student’s t-test). (B) Bar graphs illustrate one kinetic experiment indicating the percentage of cells in G1, S, and G2/M cell cycle phases after
serum stimulation, at different time points, as indicated, in cells transfected with non-targeting siRNA (top) or Syntenin si RNA (bottom). (C) Western blot comparing
the expression levels of different cell cycle markers, as indicated, in control cells (Si Ctrl) and Syntenin-depleted (si Syntenin) cells. Tubulin was used as loading
control. Note that the expression of Cyclin D2, CDK4, and Rb is downregulated in syntenin-depleted cells. (D) Bar graph indicating the expression level of cell cycle
markers in Syntenin-depleted cells relative to controls (taken as 100%). n = 3, 4, and 5 for Cyclin D2, Rb, and CDK4, respectively, bars represent mean value ± SD,
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 (Student’s t-test).
interaction in the migratory potential of colon cancer cells, an
observation directly in favor of our hypothesis that syntenin
eﬀects in cancer cells are primarily due to its eﬀects on syndecan
metabolism. Our results with the MCF7 breast cancer cells
corroborate pioneer data from Koo et al. (2002) and more recent
data by Yang et al. (2013). Indeed, Koo et al. (2002) identiﬁed
syntenin by diﬀerential gene expression proﬁle as a metastasis-
related gene in breast cancer cells. They showed that gain of
syntenin expression in MCF7 cells stimulates their migration and
invasion in transwell assays. Moreover they identiﬁed syntenin
PDZ2 domain, the syndecan high-aﬃnity interacting domain of
syntenin (Grootjans et al., 1997, 2000), to be responsible for the
migratory stimulating eﬀect. By studying a larger panel of breast
cancer cells, Yang et al. (2013) found that syntenin expression
levels correlate with the metastatic potential of these cells. Using
the MDA-MB-231 breast cancer cell model, they revealed the
impact of syntenin gain- and loss-of-function on the migratory
and invasive behavior of these cells. Finally, using xenografts, they
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showed that syntenin overexpression promotes tumor growth
and lung metastasis in vivo (Yang et al., 2013).
Consistent with the low migratory rate, the data presented
here show that syntenin-depleted cells present a defect in
the plasma membrane localization of active β1-integrin. This
observation is totally in line with previous data showing that,
by allowing syndecan recycling, syntenin might support HS-
dependent signaling molecules to be present and active at the
plasma membrane (Zimmermann et al., 2005) and that, integrin
traﬃcking is required for cellular adhesion and migration
(Humphries et al., 2015). Integrin related or not, we observed
a decrease in the percentage of cells in the most proliferative S
and G2/M phases and a defect in the cell cycle G1/S transition
phase in syntenin-depleted cells. We also documented that the
growth regulatory molecules and G1/S key regulators, Cyclin
D2 and CDK4 (Sherr, 1994) are downregulated upon syntenin
inhibition. Alltogether, these observations are in line with a
role for syntenin in tumor progression. Moreover, Cyclin D1
and CDK4 downregulation through syntenin depletion was
previously reported in head and neck squamous cell carcinoma
(Oyesanya et al., 2014). Cyclins D are synthesized as long as
growth factor stimulation persists. Their destruction, in response
to growth factors deprivation for example, results in the failure
of cells to enter S phase. A potential explanation for the eﬀects
of syntenin depletion on Cyclins D and CDK4 would be that
syndecan associated growth factor receptor systems such as
FGF-2-FGFR1, are directed toward degradation instead of being
recycled to the plasma membrane (Zimmermann et al., 2005).
In this manner, syntenin-depleted cells would be less able to
respond to serum stimulation and thus less able to stimulate
Cyclins D synthesis and entry into the S phase. Yet, there
is also a possible more direct explanation. Indeed, Cyclin D1
and Cyclin D2 present a class II PDZ-binding motif (PDZBM)
at their C-terminal domain (DVDI and DIDL, respectively).
A direct interaction between syntenin PDZ domains and Cyclins
D PDZBM could also control G1/S transition as syntenin
has also been detected in the nucleus (Zimmermann et al.,
2001).
In agreement with our results in MCF7 cells, a study from
Qian et al. (2013) showed that syntenin promotes MDA-MB-
231 breast cancer cells G1/S transition phase (Qian et al., 2013).
Interestingly, the authors also propose that syntenin levels in
breast cancer cells is inversely correlated to estrogen receptor
levels and propose that syntenin maintains the growth of breast
cancer cells when estrogen-signaling pathway is not available.
Although we similarly observed the negative correlation between
syntenin levels and estrogen-receptor status (data not shown),
this would not ﬁt our hypothesis that syntenin eﬀects in
cancer are supported by its eﬀect on syndecan traﬃcking. More
importantly, our results with estrogen receptor-positive MCF7
cells demonstrate that even low levels of syntenin are suﬃcient
to modulate cancer cell behavior.
CONCLUSION
Exploration of syntenin as a pharmacological target to inhibit
cancer progression is probably a valuable objective with potential
broad impact.
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